Skip to main content
  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

  • Home
  • About this Journal
    • Editorial Board
    • Meet the Editors
    • ATVB Journal History
    • General Statistics
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • Cover Art Award
    • ATVB Early Career Award
    • ATVB in Focus
    • Recent Brief Reviews of ATVB
    • Lecture Series
    • Collections
    • Recent Highlights of ATVB
    • Commentaries
    • Browse Abstracts
    • Insight into ATVB Authors
  • Resources
    • Instructions for Authors
    • Online Submission/Peer Review Site
    • Council on ATVB
    • Permissions and Rights Q&A
    • AHA Guidelines and Statements
    • Customer Service and Ordering Information
    • Author Reprints
    • International Users
    • AHA Newsroom
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
  • Facebook
  • LinkedIn
  • Twitter

  • My alerts
  • Sign In
  • Join

  • Advanced search

Header Publisher Menu

  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

Arteriosclerosis, Thrombosis, and Vascular Biology

  • My alerts
  • Sign In
  • Join

  • Facebook
  • LinkedIn
  • Twitter
  • Home
  • About this Journal
    • Editorial Board
    • Meet the Editors
    • ATVB Journal History
    • General Statistics
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • Cover Art Award
    • ATVB Early Career Award
    • ATVB in Focus
    • Recent Brief Reviews of ATVB
    • Lecture Series
    • Collections
    • Recent Highlights of ATVB
    • Commentaries
    • Browse Abstracts
    • Insight into ATVB Authors
  • Resources
    • Instructions for Authors
    • Online Submission/Peer Review Site
    • Council on ATVB
    • Permissions and Rights Q&A
    • AHA Guidelines and Statements
    • Customer Service and Ordering Information
    • Author Reprints
    • International Users
    • AHA Newsroom
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
Atherosclerosis and Lipoproteins

Autosomal Genome-Wide Scan for Coronary Artery Calcification Loci in Sibships at High Risk for Hypertension

Leslie A. Lange, Ethan M. Lange, Lawrence F. Bielak, Carl D. Langefeld, Sharon L. Kardia, Patrick Royston, Stephen T. Turner, Patrick F. Sheedy, Eric Boerwinkle, Patricia A. Peyser
Download PDF
https://doi.org/10.1161/hq0302.105721
Arteriosclerosis, Thrombosis, and Vascular Biology. 2002;22:418-423
Originally published March 1, 2002
Leslie A. Lange
From the Sections on Epidemiology and Biostatistics (L.A.L., E.M.L., C.D.L.), Department of Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, NC; the Department of Epidemiology (L.F.B., S.L.K., P.A.P.), School of Public Health, University of Michigan, Ann Arbor; the Medical Research Council Clinical Trials Unit (P.R.), London, UK; the Division of Hypertension and Department of Internal Medicine (S.T.T.) and Department of Diagnostic Radiology (P.F.S.), Mayo Clinic and Foundation, Rochester, Minn; and the Human Genetics Center and Institute of Molecular Medicine (E.B.), University of Texas Houston Health Science Center, Houston.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ethan M. Lange
From the Sections on Epidemiology and Biostatistics (L.A.L., E.M.L., C.D.L.), Department of Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, NC; the Department of Epidemiology (L.F.B., S.L.K., P.A.P.), School of Public Health, University of Michigan, Ann Arbor; the Medical Research Council Clinical Trials Unit (P.R.), London, UK; the Division of Hypertension and Department of Internal Medicine (S.T.T.) and Department of Diagnostic Radiology (P.F.S.), Mayo Clinic and Foundation, Rochester, Minn; and the Human Genetics Center and Institute of Molecular Medicine (E.B.), University of Texas Houston Health Science Center, Houston.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lawrence F. Bielak
From the Sections on Epidemiology and Biostatistics (L.A.L., E.M.L., C.D.L.), Department of Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, NC; the Department of Epidemiology (L.F.B., S.L.K., P.A.P.), School of Public Health, University of Michigan, Ann Arbor; the Medical Research Council Clinical Trials Unit (P.R.), London, UK; the Division of Hypertension and Department of Internal Medicine (S.T.T.) and Department of Diagnostic Radiology (P.F.S.), Mayo Clinic and Foundation, Rochester, Minn; and the Human Genetics Center and Institute of Molecular Medicine (E.B.), University of Texas Houston Health Science Center, Houston.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carl D. Langefeld
From the Sections on Epidemiology and Biostatistics (L.A.L., E.M.L., C.D.L.), Department of Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, NC; the Department of Epidemiology (L.F.B., S.L.K., P.A.P.), School of Public Health, University of Michigan, Ann Arbor; the Medical Research Council Clinical Trials Unit (P.R.), London, UK; the Division of Hypertension and Department of Internal Medicine (S.T.T.) and Department of Diagnostic Radiology (P.F.S.), Mayo Clinic and Foundation, Rochester, Minn; and the Human Genetics Center and Institute of Molecular Medicine (E.B.), University of Texas Houston Health Science Center, Houston.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sharon L. Kardia
From the Sections on Epidemiology and Biostatistics (L.A.L., E.M.L., C.D.L.), Department of Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, NC; the Department of Epidemiology (L.F.B., S.L.K., P.A.P.), School of Public Health, University of Michigan, Ann Arbor; the Medical Research Council Clinical Trials Unit (P.R.), London, UK; the Division of Hypertension and Department of Internal Medicine (S.T.T.) and Department of Diagnostic Radiology (P.F.S.), Mayo Clinic and Foundation, Rochester, Minn; and the Human Genetics Center and Institute of Molecular Medicine (E.B.), University of Texas Houston Health Science Center, Houston.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patrick Royston
From the Sections on Epidemiology and Biostatistics (L.A.L., E.M.L., C.D.L.), Department of Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, NC; the Department of Epidemiology (L.F.B., S.L.K., P.A.P.), School of Public Health, University of Michigan, Ann Arbor; the Medical Research Council Clinical Trials Unit (P.R.), London, UK; the Division of Hypertension and Department of Internal Medicine (S.T.T.) and Department of Diagnostic Radiology (P.F.S.), Mayo Clinic and Foundation, Rochester, Minn; and the Human Genetics Center and Institute of Molecular Medicine (E.B.), University of Texas Houston Health Science Center, Houston.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephen T. Turner
From the Sections on Epidemiology and Biostatistics (L.A.L., E.M.L., C.D.L.), Department of Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, NC; the Department of Epidemiology (L.F.B., S.L.K., P.A.P.), School of Public Health, University of Michigan, Ann Arbor; the Medical Research Council Clinical Trials Unit (P.R.), London, UK; the Division of Hypertension and Department of Internal Medicine (S.T.T.) and Department of Diagnostic Radiology (P.F.S.), Mayo Clinic and Foundation, Rochester, Minn; and the Human Genetics Center and Institute of Molecular Medicine (E.B.), University of Texas Houston Health Science Center, Houston.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patrick F. Sheedy
From the Sections on Epidemiology and Biostatistics (L.A.L., E.M.L., C.D.L.), Department of Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, NC; the Department of Epidemiology (L.F.B., S.L.K., P.A.P.), School of Public Health, University of Michigan, Ann Arbor; the Medical Research Council Clinical Trials Unit (P.R.), London, UK; the Division of Hypertension and Department of Internal Medicine (S.T.T.) and Department of Diagnostic Radiology (P.F.S.), Mayo Clinic and Foundation, Rochester, Minn; and the Human Genetics Center and Institute of Molecular Medicine (E.B.), University of Texas Houston Health Science Center, Houston.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eric Boerwinkle
From the Sections on Epidemiology and Biostatistics (L.A.L., E.M.L., C.D.L.), Department of Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, NC; the Department of Epidemiology (L.F.B., S.L.K., P.A.P.), School of Public Health, University of Michigan, Ann Arbor; the Medical Research Council Clinical Trials Unit (P.R.), London, UK; the Division of Hypertension and Department of Internal Medicine (S.T.T.) and Department of Diagnostic Radiology (P.F.S.), Mayo Clinic and Foundation, Rochester, Minn; and the Human Genetics Center and Institute of Molecular Medicine (E.B.), University of Texas Houston Health Science Center, Houston.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patricia A. Peyser
From the Sections on Epidemiology and Biostatistics (L.A.L., E.M.L., C.D.L.), Department of Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, NC; the Department of Epidemiology (L.F.B., S.L.K., P.A.P.), School of Public Health, University of Michigan, Ann Arbor; the Medical Research Council Clinical Trials Unit (P.R.), London, UK; the Division of Hypertension and Department of Internal Medicine (S.T.T.) and Department of Diagnostic Radiology (P.F.S.), Mayo Clinic and Foundation, Rochester, Minn; and the Human Genetics Center and Institute of Molecular Medicine (E.B.), University of Texas Houston Health Science Center, Houston.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Supplemental Materials
  • Info & Metrics
  • eLetters

Jump to

  • Article
    • Abstract
    • Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Tables
  • Supplemental Materials
  • Info & Metrics
  • eLetters
Loading

Abstract

Abstract— Coronary artery disease (CAD) is the leading cause of mortality in the developed world. Although several CAD risk factors, including measures of lipid metabolism, obesity, and blood pressure, have a genetic basis, many genes for CAD susceptibility have yet to be identified. Coronary atherosclerosis is the major cause of CAD, but many with coronary atherosclerosis lack symptoms. Thus, a major limitation of using symptomatic CAD endpoints (eg, sudden coronary death, myocardial infarction) as a study outcome is substantial disease misclassification. Coronary artery calcification (CAC) is part of the atherosclerotic process and is an independent predictor of CAD endpoints. In the present study, CAC was noninvasively quantified by electron beam computed tomography. We performed genome-wide multipoint mode-of-inheritance-free linkage analysis on affected sib pairs, defined as being ≥ the 70th sex- and age-specific percentile for CAC quantity, in a sample of 29 families enriched for hypertension. Almost 95% of participants were asymptomatic for CAD. Our LOD score (log10 odds in favor of linkage) results provide evidence that chromosomal regions 6p21.3 (maximum LOD score=2.22, P=0.00070) and 10q21.3 (maximum LOD score=3.24, P=0.000057) may harbor genes associated with subclinical coronary atherosclerosis.

  • atherosclerosis
  • coronary artery disease
  • coronary artery calcification
  • electron beam computed tomography
  • genome-wide scan

Atherosclerosis, the major cause of coronary artery disease (CAD), is influenced by the complex interplay of numerous environmental and genetic factors.1 Individual gene effects are thought to be relatively small with many depending on environmental and genetic contexts. Several CAD risk factors have a genetic basis.2–4⇓⇓ Known risk factors for CAD, however, fail to identify a large proportion of individuals with symptomatic CAD endpoints such as sudden coronary death and myocardial infarction (MI).5 A major limitation of using CAD endpoints as a study outcome is substantial disease misclassification, because many individuals with coronary atherosclerosis are asymptomatic. One half of sudden coronary deaths and one half of first myocardial infarctions occur in persons without previous symptoms.6

See page 359

Coronary artery calcification (CAC), a marker of atherosclerosis, can be quantified noninvasively and accurately by electron beam computed tomography (EBCT). CAC is an active and regulated process similar to bone mineralization.7 A direct relationship exists between CAC and both histologic and in vivo intravascular ultrasound measures of atherosclerotic plaque.8

CAC quantity is an independent predictor of angiographically defined CAD.9,10⇓ Debiased estimates for sensitivity and specificity to detect ≥50% stenosis are 97% and 72%, respectively.10 The inter- and intra-observer reliability for CAC measured by EBCT exceed 99% for all arteries combined.11 CAC predicts future CAD endpoints in asymptomatic and symptomatic adults.12,13⇓ Although many known CAD risk factors such as male sex, older age, smoking, abnormal lipid levels, high blood pressure, and ponderosity are related to CAC quantity, much variation in CAC quantity remains unexplained after accounting for these measures.14–18⇓⇓⇓⇓ Noise or artifact in EBCT measures of CAC quantity accounts for only a small amount of variability unexplained by CAD risk factors.14

Wagenknecht et al19 observed that CAC quantity clusters in families enriched for type 2 diabetes mellitus, independent of other risk factors, with an estimated heritability of 0.50. Apolipoprotein E genotype was found to influence the relationship between CAC presence and risk factors.20 Ellsworth et al21 reported a significant association between the S128R polymorphism of the E-selectin gene and presence of CAC in asymptomatic women 50 years old or younger. Pfohl et al22 reported an association between the insertion/deletion polymorphism of the angiotensin I-converting enzyme (ACE) gene and presence and quantity of CAC. Evidence for an interaction effect between paraoxonase-1 genotype and paraoxonase-2, and methylenetetrahydrofolate reductase genotypes has been reported.23 Despite these studies, the genetic basis of CAC is largely unknown.

No studies to date have reported on genome scans of CAC. We present here results from the first linkage genome scan searching for genes associated with CAC.

Methods

Subjects

Siblings in this study were participants in the Genetic Epidemiology Network of Arteriopathy (GENOA) study that began in 1995.24 Eligibility criteria for sibships included: at least two siblings with essential hypertension clinically diagnosed before age 60 years. All hypertensive and normotensive siblings in these sibships were eligible to participate. All GENOA participants were genotyped. Two hundred ninety-eight individuals (150 women) from 105 GENOA sibships (consisting of 375 individuals) also participated in the Epidemiology of Coronary Artery Calcification (ECAC) study17 and had EBCT examinations for CAC between 1992 and 1999, either before or during their participation in the GENOA study. Eligibility for the EBCT examination included not being pregnant or lactating and not having a history of coronary or noncoronary heart surgery. Because hypertension is positively associated with increased CAC levels,25 this study group is likely enriched for high levels of CAC. All siblings were white and from the Rochester, Minn, area. The final linkage analysis sample consisted of those sibships in which at least two siblings met our affected status criteria (see statistical analysis section). This requirement resulted in 29 sibships (94 individuals). Parental phenotype and genotype information were unavailable. Mayo Clinic and University of Michigan Institutional Review Boards approved study protocols, and participants gave written, informed consent after study procedures were explained.

Genotyping

A total of 370 highly polymorphic autosomal microsatellite markers (CHLC/Weber screening set 8.0) were genotyped by using standard polymerase chain reaction-based methods. Marker order was provided by the Center for Genetics at Marshfield Medical Research Foundation (www.marshmed.org/genetics). Distances between markers were based on families from the Center d’Etude du Polymorphisme Humain.26 Allele frequencies were estimated from the total GENOA sample.

EBCT

CAC was measured with a C-100 or C-150 EBCT scanner (Imatron Inc). A scan run consisted of 40 contiguous, 3-mm-thick transverse 2-dimensional image tomograms obtained from the level of the right branch of the pulmonary artery to the apex of the heart. A CAC focus was defined as an area of at least four adjacent pixels with CT number above 130 Hounsfield units in an epicardial artery. A score for each focus of CAC was calculated by multiplying the focus area (in mm2) by a density measure defined by the peak CT number in the focus as described by Agatston et al.27 Total CAC score was calculated as the sum of scores for all foci in the epicardial arteries.27

Statistical Analysis

We performed qualitative mode-of-inheritance-free linkage analysis. Affection status was defined by using sex- and age-specific CAC score percentiles estimated with the method of Royston.28 This method was applied to the first 1219 asymptomatic, white participants in the ECAC study who were selected independently of risk factor status,10 and coefficients from the model were then applied to data for the current study group. The age-specific 50th, 70th, and 90th percentiles are shown in Figure 1 for 623 women and in Figure 2 for 596 men in the ECAC study. (Also, see Tables I and II, http://atvb.ahajournals.org.) Individuals in the present study with CAC and an estimated sex- and age-specific percentile ≥70, which was chosen a priori to the linkage analysis (see Discussion), were considered affected. All others were considered unaffected.

Figure1
  • Download figure
  • Open in new tab
  • Download powerpoint

Figure 1. The 50th, 70th, and 90th percentiles for coronary artery calcification score based on 623 asymptomatic, white women from the Epidemiology of Coronary Artery Calcification Study. The 50th percentile score is zero until age 63 years, the 70th percentile score is zero until age 55 years, and the 90th percentile score is zero until age 44 years.

Figure2
  • Download figure
  • Open in new tab
  • Download powerpoint

Figure 2. The 50th, 70th and 90th percentiles for coronary artery calcification score based on 596 asymptomatic, white men from the Epidemiology of Coronary Artery Calcification Study. The 50th percentile score is zero until age 48 years, the 70th percentile score is zero until age 40 years, and the 90th percentile score is zero until age 28 years.

Multipoint linkage analysis was conducted with the maximum LOD score (MLS) method for affected sib pairs where LOD is log10 odds in favor of linkage.29,30⇓ Results are reported in terms of MLS values and their associated P values. Parameter optimizations for these analyses were restricted by using Holmans possible triangle model.31 Weighted multipoint MLS values were calculated by using GENEHUNTER version 2.0β.32

Because the maximum MLS value on chromosome 10 was achieved on the boundary of the parameter space for Z0, Z1, and Z2 (the estimated probability that two affected siblings share 0, 1, or 2 alleles identical by descent, respectively), there was concern about the accuracy of the MLS estimate at this location. We simulated 100 000 random replicate data sets on chromosome 10 using the method of gene dropping.33 The MLS value at position 91.8 cm in each random replicate data set was computed and then compared with the test statistic, the observed MLS value at 91.8 cm. An empirical P value was calculated and the corresponding 95% confidence interval (CI) constructed. Simulation studies were also performed to estimate the probability of observing our two largest MLS values in a genome-wide linkage scan in the absence of linkage. These genome-wide significance estimates were based on 10 000 random replicate data sets covering all 22 chromosomes.

Results

Twenty sibships had two affected siblings, 8 sibships had 3 affected siblings, and 1 sibship had 6 affected siblings. There were 70 affected siblings and 24 unaffected siblings in these 29 sibships, and only 5 participants had a history of MI. Selected sample descriptives for those classified as affected and unaffected are in Table 1. Genotype information was included on an additional 16 siblings in these sibships who were not examined with EBCT but were genotyped as part of the GENOA study. For these 16 individuals, their phenotypes were recorded as unknown.

View this table:
  • View inline
  • View popup
Table 1.

Sample Descriptives by Affection Status for 94 Participants with CAC Data

The number of markers ranged from 30 on chromosome 1 to 6 on chromosomes 21 and 22. The average distance between markers ranged from 8.3 cm on chromosome 17 to 10.4 cm on chromosome 11. The maximum distance between adjacent markers ranged from 14 cm on chromosomes 11 and 14 to 26 cm on chromosome 9.

MLS results are illustrated in Figure 3. The largest multipoint MLS values, the corresponding parameter estimates for Z0, Z1, Z2 and location are presented for each chromosome in Table 2. A MLS value of 2.22 (P=0.00070) was observed on chromosome 6 at map position 76.4 cm (Figure 4) between markers D6S1053 and D6S1031. The overall largest MLS value was 3.24 (P=0.000057) at 91.8 cm between markers D10S1432 and D10S2327 on chromosome 10 (Figure 5). This MLS value was achieved on the boundary of the parameter space for Z0, Z1, and Z2 (Zˆ0= 0.00, Zˆ1= 0.50, and Zˆ2= 0.50). An empirical P value of 0.00012 (95% CI, 0.00010, 0.00014) was obtained at 91.8 cm based on a simulation study.

Figure3
  • Download figure
  • Open in new tab
  • Download powerpoint

Figure 3. Multipoint MLS curves for chromosomes 1 to 22. The strongest evidence for linkage was observed on chromosomes 6 and 10.

View this table:
  • View inline
  • View popup
Table 2.

Largest Multipoint MLS Value and Associated P Value, by Chromosome

Figure4
  • Download figure
  • Open in new tab
  • Download powerpoint

Figure 4. Multipoint MLS curve for chromosome 6. Marker names and positions are given at the top of the graph. The peak of the MLS curve localized between D6S1053 and D6S1031 at map position 76.4 cm.

Figure5
  • Download figure
  • Open in new tab
  • Download powerpoint

Figure 5. Multipoint MLS curve for chromosome 10. Marker names and positions are given at the top of the graph. The peak of the MLS curve localized between D10S1432 and D10S2327 at map position 91.8 cm.

Removing the 1 sibship with 6 affected siblings and repeating the genome wide linkage scan did not change the inferences. Excluding this sibship resulted in a slightly increased MLS value (P=0.00054) on chromosome 6 and a slightly decreased MLS value (P=0.00032) on chromosome 10 with the maximum likelihood estimates remaining on the boundary.

Four other MLS values greater than 1.0 were observed by using all 29 sibships. These were observed on chromosomes 2 (MLS=1.16 at 114.4 cm), 14 (MLS=1.16 at 95.4 cm), 15 (MLS=1.10 at 8.0 cm) and 17 (MLS=1.13 at 29.4 cm).

We calculated empirical genome-wide significance estimates of our largest MLS values. We estimated the probability (95% CI) of observing MLS values at least as large as 2.22 and 3.24 anywhere along the 22 chromosomes by chance alone to be 0.074 (0.067, 0.085) and 0.0090 (0.0064, 0.012), respectively.

Discussion

Our strategy for linkage analyses was dictated by the distribution of the CAC measurements. Approximately one third of the 298 participants did not have measurable CAC. Thus, standard linkage methods for quantitative traits, which are based on linear regression or variance components techniques, were inappropriate because such methods are highly sensitive to departures from normality in the distribution of the quantitative trait. Risch and Zhang34 advocate the use of highly discordant sib pairs in mapping quantitative trait loci. Ascertaining discordant sib pairs, with one sibling in the highest decile and one sibling in the lowest decile, is very difficult; we had very few such pairings. In fact, the large numbers of individuals with undetectable CAC made it very difficult to identify percentiles in the lower tail of the percentile distribution. Furthermore, the assumption that use of discordant sib pairs increases power to detect linkage may be suspect. Wagenknecht et al19 provided evidence that factors associated with presence and absence of CAC differ from those associated with quantity of CAC in those with measurable CAC. Should dissimilar mechanisms for CAC development and the extent of CAC quantity exist, including sib pairs discordant for their percentile scores could decrease the power to detect linkage.

We chose to focus on individuals above the 70th percentile of the CAC score distribution, thus selecting individuals in whom the CAC process had taken place for a prolonged period. The 70th percentile identifies those considered to be in the highest risk group for a future event. According to the Third Report of the National Cholesterol Education Program,35 anyone with a 10-year risk of CAD >20% is in the highest risk group. Raggi et al36 present estimated annual risks for fatal and non-fatal MI for different CAC percentiles. Those at or above the 70th percentile clearly meet National Cholesterol Education Program criteria for being at highest risk for an event. In our ECAC study, the 70th percentile cutoff was statistically significantly associated with occurrence of CAD events after an average of five years, after adjusting for Framingham risk (OR, 2.8; 95% CI, 1.2 to 6.4) (P.A. Peyser, unpublished data, 2001). Hoff et al37 recently reported that the 75th percentile is a very sensitive cutoff point for identifying subjects at greatest risk. The inferences from our study were the same with either the 60th or 80th percentile (data not shown).

A region on chromosome 10 is significantly linked and a region on chromosome 6 is suggestive of linkage to genes that influence CAC differences in our study group of individuals at high risk of hypertension and CAD. Although hypertension promotes atherosclerosis in the aorta and other arteries, the linkage findings apply only to detectable calcification in the coronary arteries. Candidate genes for CAC include genes involved in hypertension, the immune system, and bone mineralization processes. Candidate genes within the region of interest on chromosome 6 include collagen type XI α2 (OMIM #120290) and allograft inflammatory factor 1 (OMIM #601833). Candidate genes within the region of interest on chromosome 10 include collagen type XIII α1 (OMIM #120350) and bone morphogenetic protein receptor type 1A (OMIM #601299). Collagen plays a role in atherosclerosis by forming a fibrous cap around the lipid core and contributes to vascular stiffness. Allograft inflammatory factor 1 represents a cytokine-inducible, tissue-specific, and highly conserved transcript transiently expressed in response to vascular trauma.38 Bone morphogenetic protein receptors are involved in bone formation,39 and their associated proteins are expressed in calcified human atherosclerotic plaque.40 A candidate gene within the peak region on chromosome 17p12 is a gene linked to abdominal obesity-metabolic syndrome. This gene may be associated with leptin levels,41 which have been shown to influence the calcification of vascular cells.42 We found no evidence for linkage (MLS values <0.5) in the chromosomal regions for apolipoprotein E, E-selectin, angiotensin converting enzyme, paraoxonase-1, paraoxonase-2, or methylenetetrahydrofolate reductase, which are candidate genes for CAC.20–23⇓⇓⇓

Hypertension is independently associated with CAC after adjusting for other CAD risk factors.25 The magnitude of our linkage results, the modest number of sibships used in our analyses, and the high prevalence of hypertension may suggest that hypertension directly or indirectly increases the penetrance of genes influencing CAC. Interestingly, only modest evidence for linkage for hypertension status has been detected by using GENOA sibships in an unpublished genome-wide linkage scan (S.L. Kardia, unpublished data, 2001). Xu et al43 reported evidence of linkage for hypertension on chromosomes 3, 11, 15, 16, and 17 from a genome-wide scan in a large sample of Chinese hypertensive sib pairs. Our linkage peak for CAC on chromosome 17 (MLS=1.17) was observed in a very similar location (within 9 cm) to the peak results on chromosome 17 (MLS=2.16) from Xu et al.43 Krushkal et al44 observed evidence for linkage to genes that influence inter-individual systolic blood pressure variation on chromosomes 2, 5, 6, and 15. Although we observed suggestive linkage results on chromosomes 2, 6, and 15, the location of our peaks did not overlap described regions of Krushkal et al.44 Our peak region on chromosome 2 did, however, overlap the marker D2S1790 (MLS=1.01 at D2S1790), which was found to be significantly linked to diastolic blood pressure in two independent studies.4,45⇓

Studying a measure of subclinical atherosclerosis can identify genes acting through pathways of measurable atherosclerosis risk factors or through novel pathways that have not or cannot be directly measured in vivo. Our genome-wide linkage results provide regions of focus for future genetic studies of subclinical atherosclerosis. We identified two regions with stronger evidence of linkage and several regions with weaker evidence of linkage that require verification and additional testing. The CAC process has a complex etiology, likely influenced by the interaction of numerous environmental and genetic factors. Our findings, particularly the linkage result on chromosome 10, suggest a potentially strong genetic component for a high CAC percentile in individuals at increased risk for hypertension. Identification of genes that contribute to the CAC process should provide a better understanding of the origin of CAC and could ultimately establish a basis for improved prevention and treatment of asymptomatic coronary atherosclerosis.

Acknowledgments

This study was supported by United States National Institutes of Health grants R01 HL46292, U01 HL054481, U01 HL054464, U01 HL054457, and by General Clinical Research Center Grant M01 RR00585 also from the National Institutes of Health. L.A.L. was partially supported by a University of Michigan Regents Fellowship and a University of Michigan Rackham Dissertation Fellowship.

Footnotes

  • Received December 17, 2001; revision accepted January 14, 2002.

References

  1. ↵
    Peyser PA. Genetic epidemiology of coronary artery disease. Epidemiol Rev. 1997; 19: 80–90.
    OpenUrlFREE Full Text
  2. ↵
    Chagnon YC, Perusse L, Weisnagel SJ, Rankinen T, Bouchard C. The human obesity gene map: the 1999 update. Obes Res. 1999; 8: 89–117.
    OpenUrl
  3. ↵
    Almasy L, Hixson JE, Rainwater DL, Cole S, Williams JT, Mahaney MC, VandeBerg JL, Stern MP, MacCluer JW, Blangero J. Human pedigree-based quantitative-trait-locus mapping: localization of two genes influencing HDL-cholesterol metabolism. Am J Hum Genet. 1999; 64: 1686–1693.
    OpenUrlCrossRefPubMed
  4. ↵
    Rice T, Rankinen T, Province MA, Chagnon YC, Perusse L, Borecki IB, Bouchard C, Rao DC. Genome-wide linkage analysis of systolic and diastolic blood pressure: the Quebec Family Study. Circulation. 2000; 102: 1956–1963.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    Grover SA, Coupal L, Hu XP. Identifying adults at increased risk of coronary disease: how well do the current cholesterol guidelines work? JAMA. 1995; 274: 801–806.
    OpenUrlCrossRefPubMed
  6. ↵
    Devereux RB, Alderman MH. Role of preclinical cardiovascular disease in the evolution from risk factor exposure to development of morbid events. Circulation. 1993; 88: 1444–1445.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    Wexler L, Brundage B, Crouse J, Detrano R, Fuster V, Maddahi J, Rumberger J, Stanford W, White R, Taubert K. Coronary artery calcification: pathophysiology, epidemiology, imaging methods and clinical implications. Circulation. 1996; 94: 1175–1192.
    OpenUrlFREE Full Text
  8. ↵
    Rumberger JA, Brundage BH, Rader DJ, Kondos G. Electron beam computed tomographic coronary calcium scanning: a review and guidelines for use in asymptomatic persons. Mayo Clin Proc. 1999; 74: 243–252.
    OpenUrlCrossRefPubMed
  9. ↵
    Guerci AD, Arad Y, Agatston A. Predictive value of EBCT scanning. Circulation. 1998; 97: 2583–2584.
    OpenUrlFREE Full Text
  10. ↵
    Bielak LF, Rumberger JA, Sheedy PFII, Schwartz RS, Peyser PA. Probabilistic model for prediction of angiographically defined obstructive coronary artery disease using electron beam computed tomography calcium score strata. Circulation. 2000; 102: 380–385.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    Kaufmann RB, Sheedy PFII, Breen JF, Kelzenberg JR, Kruger BL, Schwartz RS, Moll PP. Detection of heart calcification with electron beam CT: interobserver and intraobserver reliability for scoring quantification. Radiology. 1994; 190: 347–352.
    OpenUrlCrossRefPubMed
  12. ↵
    Detrano R, Hsiai T, Wang S, Puentes G, Fallavollita J, Shields P, Stanford W, Wolfkiel C, Georgiou D, Budoff M, Reed J. Prognostic value of coronary calcification and angiographic stenoses in patients undergoing coronary angiography. J Am Coll Cardiol. 1996; 27: 285–290.
    OpenUrlPubMed
  13. ↵
    Arad Y, Spadaro LA, Goodman K, Newstein D, Guerci AD. Prediction of coronary events with electron beam computed tomography. J Am Coll Cardiol. 2000; 36: 1253–1260.
    OpenUrlCrossRefPubMed
  14. ↵
    Maher JE, Raz JA, Bielak LF, Sheedy PFII, Schwartz RS, Peyser PA. Potential of quantity of coronary artery calcification to identify new risk factors for asymptomatic atherosclerosis. Am J Epidemiol. 1996; 144: 943–953.
    OpenUrlAbstract/FREE Full Text
  15. ↵
    Kuller LH, Matthews KA, Sutton-Tyrrell K, Edmundowicz D, Bunker CH. Coronary and aortic calcification among women 8 years after menopause and their premenopausal risk factors: the Healthy Women Study. Arterioscler Thromb VascBiol. 1999; 19: 2189–2198.
    OpenUrlAbstract/FREE Full Text
  16. ↵
    Bild DE, Folsom AR, Lowe LP, Sidney S, Kiefe C, Westfall AO, Zheng ZJ, Rumberger J. Prevalence and correlates of coronary calcification in black and white young adults: the Coronary Artery Risk Development in Young Adults (CARDIA) Study. Arterioscler Thromb Vasc Biol. 2001; 21: 852–857.
    OpenUrlAbstract/FREE Full Text
  17. ↵
    Bielak LF, Klee GG, Sheedy PFII, Turner ST, Schwartz RS, Peyser PA. Association of fibrinogen with quantity of coronary artery calcification measured by electron beam computed tomography. Arterioscler Thromb Vasc Biol. 2000; 20: 2167–2171.
    OpenUrlAbstract/FREE Full Text
  18. ↵
    Valdes AM, Wolfe ML, Tate HC, Gefter W, Rut A, Rader DJ. Association of traditional risk factors with coronary calcification in persons with a family history of premature coronary heart disease: the study of the inherited risk of coronary atherosclerosis. J Investig Med. 2001; 49: 353–361.
    OpenUrlCrossRefPubMed
  19. ↵
    Wagenknecht LE, Bowden DW, Carr JJ, Langefeld CD, Freedman BI, Rich SS.3 Familial aggregation of coronary artery calcium in families with type 2 diabetes. Diabetes. 2001; 50: 861–866.
    OpenUrlAbstract/FREE Full Text
  20. ↵
    Kardia SLR, Haviland MB, Ferrell RE, Sing CF. The relationship between risk factor levels and presence of coronary artery calcification is dependent on apolipoprotein E genotype. Arterioscler Thromb Vasc Biol. 1999; 19: 427–435.
    OpenUrlAbstract/FREE Full Text
  21. ↵
    Ellsworth DL, Bielak LF, Turner ST, Sheedy PFII, Boerwinkle E, Peyser PA. Gender- and age-dependent relationships between the E-selectin S128R polymorphism and coronary artery calcification. J Mol Med. 2001; 79: 390–398.
    OpenUrlCrossRefPubMed
  22. ↵
    Pfohl M, Athanasiadis A, Koch M, Clemens P, Benda N, Haring HU, Karsch KR. Insertion/deletion polymorphism of the angiotensin I-converting enzyme gene is associated with coronary artery plaque calcification as assessed by intravascular ultrasound. J Am Coll Cardiol. 1998; 31: 987–991.
    OpenUrlCrossRefPubMed
  23. ↵
    Reilly MP, Wolfe ML, Picoult-Newberg L, de Lemos AS, Mohler ER, Pohl M, Grant DM, Gefter W, Boyce-Jacino M, Rader DJ. Interaction of the paraoxonase genes PON1, and PON2, and the methylenetetrahydrofolate reductase gene and association with coronary artery calcification using electron-beam computed tomography. Am J Cardiol. 2001; 88: 84E.
    OpenUrl
  24. ↵
    The FBPP Investigators. Multi-center genetic study of hypertension: the Family Blood Pressure Program (FBPP). Hypertension. 2002; 39: 3–9.
    OpenUrlAbstract/FREE Full Text
  25. ↵
    Jamjoum LS. Relationship of blood pressure level and hypertension to coronary artery calcification [thesis]. Ann Arbor, Mich: University of Michigan; 2000.
  26. ↵
    Broman KW, Murray JC, Sheffield VC, White RL, Weber JL. Comprehensive human genetic maps: individual and sex-specific variation in recombination. Am J Hum Genet. 1998; 63: 861–869.
    OpenUrlCrossRefPubMed
  27. ↵
    Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M, Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol. 1990; 15: 827–832.
    OpenUrlCrossRefPubMed
  28. ↵
    Royston P. A parametric model for ordinal response data, with application to estimating age-specific reference intervals. Biostatistics. 2001; 1: 263–277.
    OpenUrl
  29. ↵
    Risch N. Linkage strategies for genetically complex traits, II: the power of affected relative pair. Am J Hum Genet. 1990; 46: 229–241.
    OpenUrlPubMed
  30. ↵
    Risch N. Linkage strategies for genetically complex traits, III: the effect of marker polymorphism on analysis of affected relative pairs. Am J Hum Genet. 1990; 46: 242–253.
    OpenUrlPubMed
  31. ↵
    Holmans P. Asymptotic properties of affected-sib-pair linkage analysis. Am J Hum Genet. 1993; 52: 362–374.
    OpenUrlPubMed
  32. ↵
    Kruglyak L, Daly MJ, Reeve-Daly MP, Lander ES. Parametric and nonparametric linkage analysis: a unified multipoint approach. Am J Hum Genet. 1996; 58: 1347–1363.
    OpenUrlPubMed
  33. ↵
    Xu J, Meyers D, Freije D, Isaacs S, Wiley K, Nusskem D, Ewing C, Wilkins E, Bujnovszky P, Bova GS, Walsh P, Isaacs W, Schleutker J, Matikainen M, Tammela T, Visakorpi T, Kallioniemi OP, Berry R, Schaid D, French A, McDonnell S, Schroeder J, Blute M, Thibodeau S, Grönberg H, Emanuelsson M, Damber JE, Bergh A, Jonsson BA, Smith J, Bailey-Wilson J, Carpten J, Stephan D, Gillanders E, Amundson I, Kainu T, Freas-Lutz D, Baffoe-Bonnie A, Van Aucken A, Sood R, Collins F, Brownstein M, Trent J. Evidence for a prostate cancer susceptibility locus on the X chromosome. Nat Genet. 1998; 20: 175–179.
    OpenUrlCrossRefPubMed
  34. ↵
    Risch N, Zhang H. Extreme discordant sib pairs for mapping quantitative trait loci in humans. Science. 1995; 268: 1584–1589.
    OpenUrlAbstract/FREE Full Text
  35. ↵
    Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA. 2001; 285: 2486–2497.
    OpenUrlCrossRefPubMed
  36. ↵
    Raggi P, Cooll B, Callister TQ. Use of electron beam tomography data to develop models for prediction of hard coronary events. Am Heart J. 2001; 141:V 372–382.
    OpenUrl
  37. ↵
    Hoff JA, Chomka EV, Krainik AJ, Daviglus M, Rich S, Kondos GT. Age and gender distributions of coronary artery calcium detected by electron beam tomography in 35 246 adults. Am J Cardiol. 2001; 87: 1335–1339.
    OpenUrlCrossRefPubMed
  38. ↵
    Autieri MV. CDNA cloning of human allograft inflammatory factor-1: tissue distribution, cytokine induction, and mRNA expression in injured rat carotid arteries. Biochem Biophys Res Commun. 1996; 228: 29–37.
    OpenUrlCrossRefPubMed
  39. ↵
    Ishidou Y, Kitajima I, Obama H, Maruyama I, Murata F, Imamura T, Yamada N, ten Dijke P, Miyazono K, Sakou T. Enhanced expression of type I receptors for bone morphogenetic proteins during bone formation. J Bone Miner Res. 1995; 10: 1651–1659.
    OpenUrlPubMed
  40. ↵
    Bostrom K, Watson KE, Horn S, Wortham C, Herman IM, Demer LL. Bone morphogenetic protein expression in human atherosclerotic lesions. J Clin Invest. 1993; 91: 1800–1809.
    OpenUrlCrossRefPubMed
  41. ↵
    Kissebah AH, Sonnenberg GE, Myklebust J, Goldstein M, Broman K, James RG, Marks JA, Krakower GR, Jacob HJ, Weber J, Martin L, Blangero J, Comuzzie AG. Quantitative trait loci on chromosomes 3 and 17 influence phenotypes of metabolic syndrome. Proc Natl Acad Sci U S A. 2000; 97: 14478–14483.
    OpenUrlAbstract/FREE Full Text
  42. ↵
    Parhami F, Tintut Y, Ballard A, Fogelman AM, Demer LL. Leptin enhances the calcification of vascular cells. Circ Res. 2001; 88: 954–960.
    OpenUrlAbstract/FREE Full Text
  43. ↵
    Xu X, Rogus JJ, Terwedow HA, Yang J, Wang Z, Chen C, Niu T, Wang B, Xu H, Weiss S, Schork NJ, Fang Z. An extreme-sib-pair genome scan for genes regulating blood pressure. Am J Hum Genet. 1999; 64: 1694–1701.
    OpenUrlCrossRefPubMed
  44. ↵
    Krushkal J, Ferrell R, Mockrin SC, Turner ST, Sing CF, Boerwinkle E. Genome-wide linkage analyses of systolic blood pressure using highly discordant siblings. Circulation. 1999; 99: 1407–1410.
    OpenUrlAbstract/FREE Full Text
  45. ↵
    Atwood LD, Samollow PB, Hixson JE, Stern MP, MacCluer JW. Genome-wide linkage analysis of blood pressure in Mexican Americans. Genet Epidemiol. 2001; 20: 373–382.
    OpenUrlCrossRefPubMed
View Abstract
Back to top
Previous ArticleNext Article

This Issue

Arteriosclerosis, Thrombosis, and Vascular Biology
March 2002, Volume 22, Issue 3
  • Table of Contents
Previous ArticleNext Article

Jump to

  • Article
    • Abstract
    • Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Tables
  • Supplemental Materials
  • Info & Metrics
  • eLetters

Article Tools

  • Print
  • Citation Tools
    Autosomal Genome-Wide Scan for Coronary Artery Calcification Loci in Sibships at High Risk for Hypertension
    Leslie A. Lange, Ethan M. Lange, Lawrence F. Bielak, Carl D. Langefeld, Sharon L. Kardia, Patrick Royston, Stephen T. Turner, Patrick F. Sheedy, Eric Boerwinkle and Patricia A. Peyser
    Arteriosclerosis, Thrombosis, and Vascular Biology. 2002;22:418-423, originally published March 1, 2002
    https://doi.org/10.1161/hq0302.105721

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
  •  Download Powerpoint
  • Article Alerts
    Log in to Email Alerts with your email address.
  • Save to my folders

Share this Article

  • Email

    Thank you for your interest in spreading the word on Arteriosclerosis, Thrombosis, and Vascular Biology.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Autosomal Genome-Wide Scan for Coronary Artery Calcification Loci in Sibships at High Risk for Hypertension
    (Your Name) has sent you a message from Arteriosclerosis, Thrombosis, and Vascular Biology
    (Your Name) thought you would like to see the Arteriosclerosis, Thrombosis, and Vascular Biology web site.
  • Share on Social Media
    Autosomal Genome-Wide Scan for Coronary Artery Calcification Loci in Sibships at High Risk for Hypertension
    Leslie A. Lange, Ethan M. Lange, Lawrence F. Bielak, Carl D. Langefeld, Sharon L. Kardia, Patrick Royston, Stephen T. Turner, Patrick F. Sheedy, Eric Boerwinkle and Patricia A. Peyser
    Arteriosclerosis, Thrombosis, and Vascular Biology. 2002;22:418-423, originally published March 1, 2002
    https://doi.org/10.1161/hq0302.105721
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Related Articles

Cited By...

Subjects

  • Genetics
    • Genetics
  • Epidemiology, Lifestyle, and Prevention
    • Epidemiology
  • Imaging and Diagnostic Testing
    • Imaging
    • Computerized Tomography (CT)

Arteriosclerosis, Thrombosis, and Vascular Biology

  • About ATVB
  • Instructions for Authors
  • AHA CME
  • Meeting Abstracts
  • Permissions
  • Email Alerts
  • Open Access Information
  • AHA Journals RSS
  • AHA Newsroom

Contact the Editorial Office:
email: atvb@atvb.org

Information for:
  • Advertisers
  • Subscribers
  • Subscriber Help
  • Institutions / Librarians
  • Institutional Subscriptions FAQ
  • International Users
American Heart Association Learn and Live
National Center
7272 Greenville Ave.
Dallas, TX 75231

Customer Service

  • 1-800-AHA-USA-1
  • 1-800-242-8721
  • Local Info
  • Contact Us

About Us

Our mission is to build healthier lives, free of cardiovascular diseases and stroke. That single purpose drives all we do. The need for our work is beyond question. Find Out More about the American Heart Association

  • Careers
  • SHOP
  • Latest Heart and Stroke News
  • AHA/ASA Media Newsroom

Our Sites

  • American Heart Association
  • American Stroke Association
  • For Professionals
  • More Sites

Take Action

  • Advocate
  • Donate
  • Planned Giving
  • Volunteer

Online Communities

  • AFib Support
  • Garden Community
  • Patient Support Network
  • Professional Online Network

Follow Us:

  • Follow Circulation on Twitter
  • Visit Circulation on Facebook
  • Follow Circulation on Google Plus
  • Follow Circulation on Instagram
  • Follow Circulation on Pinterest
  • Follow Circulation on YouTube
  • Rss Feeds
  • Privacy Policy
  • Copyright
  • Ethics Policy
  • Conflict of Interest Policy
  • Linking Policy
  • Diversity
  • Careers

©2018 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. The American Heart Association is a qualified 501(c)(3) tax-exempt organization.
*Red Dress™ DHHS, Go Red™ AHA; National Wear Red Day ® is a registered trademark.

  • PUTTING PATIENTS FIRST National Health Council Standards of Excellence Certification Program
  • BBB Accredited Charity
  • Comodo Secured